A genome-wide CRISPR screen reconciles the role of N-linked glycosylation in galectin-3 transport to the cell surface

Sarah E. Stewart1*, Sam A. Menzies2*, Stephanie J. Popa1, Natalia Savinykh3, Anna Petrunkina Harrison3, Paul J. Lehner2, Kevin Moreau1#

2. Department of Medicine, Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0XY, UK
3. NIHR Cambridge BRC Cell Phenotyping Hub, Department of Medicine, University of Cambridge, UK

*Co-first authors; #Lead author; for correspondence: KM: km510@cam.ac.uk

Summary statement
Using a CRISPR screen, we identified important genes that regulate the cell surface localization of Galectins and clarified the role of the glycosylation in Galectin secretion.

Abstract
Galectins are a family of lectin binding proteins expressed both intracellularly and extracellularly. Galectin-3 (Gal-3) is expressed at the cell surface, however, Gal-3 lacks a signal sequence and the mechanism of Gal-3 transport to the cell surface remain poorly understood. Here, using a genome-wide CRISPR/Cas9 forward genetic screen for regulators of Gal-3 cell surface localization we identified genes encoding glycoproteins, enzymes involved in N-linked glycosylation, regulators of ER-Golgi trafficking and proteins involved in immunity. The results of this screening approach lead us to address the controversial role of N-linked glycosylation in the transport of Gal-3 to the cell surface. We find that N-linked glycoprotein maturation is not required for Gal-3 transport from the cytosol to the extracellular space, but is important for cell surface binding. Additionally, secreted Gal-3 is...
predominantly free and not packaged into extracellular vesicles. These data support a secretion pathway independent of N-linked glycoproteins and extracellular vesicles.

**Introduction**

Galectins are an evolutionarily conserved family of β-galactose-binding proteins. There are 15 members, all of which contain a carbohydrate-recognition domain (CRD). Family members can be divided into three categories: (i) prototypic single CRD galectins that can form homodimers; (ii) the galectins that contain two tandem repeat CRDs, and (iii) galectin-3 which is a chimeric protein containing a single CRD and a disordered N-terminal region that facilitates oligomerization (Elola, Blidner, Ferragut, Bracalente, & Rabinovich, 2015).

Galectins belong to the leaderless class of proteins (defined by the absence of signal peptides and transmembrane domains) that function both in the cytoplasm and outside the cell. Their function in the cytoplasm include roles in cell growth, apoptosis, the cell cycle and cellular immunity (Boyle & Randow, 2013; Liu & Rabinovich, 2005; Nabi, Shankar, & Dennis, 2015; Rabinovich, Rubinstein, & Fainboim, 2002). When galectins are outside the cell, they are known to be retained to the extracellular leaflet of the plasma membrane, typically through their binding to N-linked glycans and core O-linked glycans on glycosylated proteins and lipids. From there, they modulate many cellular processes including endocytosis, migration and adhesion (Elola et al., 2015; Lakshminarayan et al., 2014; Mazurek et al., 2012; Xin, Dong, & Guo, 2015). In addition, galectins are also found in the serum where they regulate the activity of immune cells (Rabinovich, Rubinstein et al. 2002).

Interestingly, Gal-3 is detected at high levels in cardiac patients where it is used as a marker for cardiovascular disease and heart failure (Jagodzinski et al., 2015; Medvedeva, Berezin, Surkova, Yaranov, & Shchukin, 2016). Similarly, elevated levels of galectin-1 (Gal-1) are associated with poor prognosis in many cancers including melanoma, lung, bladder and head cancers (Thijssen, Heusschen, Caers, & Griffioen, 2015).

The mechanism of galectin secretion remains controversial. As mentioned above, galectins lack a signal peptide and do not enter the classical ER/Golgi secretory pathway (Hughes, 1999; Nickel, 2003) and their secretion is not blocked by drugs that inhibit the
classical secretory pathway such as brefeldin A and monensin (Lindstedt, Apodaca, Barondes, Mostov, & Leffler, 1993; Sato, Burdett, & Hughes, 1993).

Currently, three major mechanisms have been proposed to explain the unconventional secretion of leaderless proteins: (i) direct translocation across the plasma membrane either through a transporter or by auto-transportation as in the case of FGF2; (ii) The engulfment into extracellular vesicle (exosome and microvesicle), and (iii) the capture into a membrane bound compartment such as secretory autophagosome, a late endosome or CUPS (Hughes, 1999; Nickel & Rabouille, 2009; Nickel & Seedorf, 2008).

Evidence is lacking for a mechanism involving direct translocation of galectins across the membrane. In particular, a transporter is yet to be identified and the auto-transportation by pore formation is also lacking (Hughes, 1999; Nickel & Rabouille, 2009; Nickel & Seedorf, 2008; Rabouille, 2017). Galectin secretion via microvesicles or exosomes, collectively termed extracellular vesicles (EVs) has been proposed (Cooper & Barondes, 1990; Mehul & Hughes, 1997; Sato et al., 1993; Seelenmeyer, Stegmayer, & Nickel, 2008). Indeed, Gal-3 and Gal-1 are recruited to the cytoplasmic leaflet of the plasma membrane where they are secreted in microvesicles generated by plasma membrane budding (Cooper & Barondes, 1990; Mehul & Hughes, 1997). However, contrasting reports show that Gal-1 secretion is not reduced when plasma membrane blebbing is inhibited (Seelenmeyer et al., 2008). Furthermore, secretion in EVs does not explain how galectins are subsequently delivered to the cell surface, although the EVs may be disrupted in the extracellular space to release Gal-3 (Mehul & Hughes, 1997). It has also been proposed that Gal-1 is directly transported across the plasma membrane while coupled to glycoproteins or lipids on the inner leaflet of the membrane of the secretory vesicles. Indeed, Gal-1 secretion requires a functional CRD for cell surface localisation, and binding to glycoproteins proteins or glycolipids may recruit galectins to the inner leaflet of the plasma membrane and mediate transport across the membrane to the cell surface (Seelenmeyer et al., 2005). However, Chinese hamster ovary (CHO) cells lacking the ability to glycosylate glycoproteins efficiently secrete Gal-1 (Cho & Cummings, 1995), suggesting that the glycans do not play a role in the secretion. Therefore, not only the mechanism of galectin secretion from the cell remains elusive, but also the role of glycosylation in the secretion process.

What is better established, however, is that moieties of N-linked glycoproteins and lipids that are exposed to the extracellular leaflet of the plasma membrane are important for restricting galectins to the cell surface of cells after their secretion and prevent them to
diffuse in the extracellular medium. For instance, exogenous purified Gal-1, -3 and -8 only bind to the cell surface when N-linked glycosylation pathways are intact and N-linked glycans expressed at the cell surface (Patnaik et al., 2006).

To identify key regulators of Gal-3 cell surface localization (the sum of both its secretion and its retention) and clarify the role of glycosylation in either, we performed a genome-wide CRISPR/Cas9 forward genetic screen. The most significantly enriched genes identified in the screen encodes glycoproteins, enzymes involved in N-linked glycan maturation and proteins regulating ER-Golgi trafficking.

We focused on the role of two genes identified in the CRISPR screen that encode proteins essential for N-linked glycosylation. When N-linked glycosylation was disrupted the level of Gal-3 on the cell surface decreased. This was not due to a disruption of Gal-3 secretion from the cytosol to the extracellular space, as free Gal-3 was detected in the medium. This demonstrates that N-linked glycosylation is not required for secretion of Gal-3, but is essential for cell surface binding. These data support a model where N-linked glycosylation is not required for secretion of Gal-3 to the extracellular space. Furthermore, we tested the role of EVs in Gal-3 secretion but we conclude that they are not involved.

Results

A genome-wide screen identifies genes required for galectin-3 cell surface localization

Due to the limited knowledge about Gal-3 trafficking from the cytosol to the cell surface and its regulation, we set out to identify genes required for cell surface localization of Gal-3. At steady state suspension HeLa cells (sHeLa) express Gal-3 on their surface (figure S1A) and there is a small proportion detectable in the medium (figure S1B). To be found on the outer leaflet of cell surface, Gal-3 must be secreted from the cytosol through an unconventional protein trafficking pathway. Therefore, we performed a genome-wide CRISPR/Cas9 forward genetic screen in sHeLa and enriched for cells with decreased cell surface Gal-3 (figure 1A). To ensure optimal screening parameters, sHeLa cells stably expressing Cas9 nuclease (sHeLa-Cas9) were analysed for Gal-3 surface expression by flow cytometry. Gal-3 surface expression was largely homogenous; however, the small population of Gal-3 negative cells were removed in a pre-clear cell sort to optimize screening parameters. The resulting population (approximately 1x10^8 cells) was then transduced with
the GeCKO v2 sgRNA library, containing 123,411 guide RNAs targeting 19,050 genes, at a multiplicity of infection of approximately 0.3 (Shalem et al., 2014; Timms et al., 2016). Untransduced cells were removed through puromycin selection and rare cells that had reduced cell surface Gal-3 were enriched by two rounds of fluorescence activated cell sorting (FACS) (figure 1A and 1B). The sgRNA abundance of the enriched population was quantified by deep sequencing and compared to the control unsorted population (figure 1C) (Konig et al., 2007; Timms et al., 2016). Strikingly the most significantly enriched genes identified in this screen coded for Golgi enzymes involved in N-linked glycosylation or proteins regulating ER-Golgi transport (figure 1C and D). These include solute carrier family 35 member A2 (SLC35A2), mannosyl (alpha-1,3,4)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase (MGAT1), mannosidase alpha class 1A member 2 (MAN1A2) and component of oligomeric Golgi complex 1 (COG1) (figure 1C and 1D and table S1). To further analyze the function of the genes identified in this screen we applied bioinformatic pathway analysis to the 200 most enriched genes (Huang da, Sherman, & Lempicki, 2009a, 2009b). This analysis showed that of the genes with known function many genes coded for glycoproteins such as Integrin Subunit Beta 3 (ITGB3), Laminin Subunit Beta 2 (LAMB2) and basigin (CD147), or proteins involved in the transport of glycoproteins within the Golgi and to the cell surface including ADP-riboseylation factor 1 (ARF1) and ADP-riboseylation factor 1 Like GTPase 3 (ARL3) and proteins with roles in immunity including NLR Family Pyrin Domain Containing 2 (NLRP2) and Tripartite Motif Containing 5 and 34 (TRIM5, TRIM34) (table 1). Interestingly, several proteins identified in this screen are known Gal-3 interactors either on cell surface such as the integrins, laminins and CD147 or in the cytosol for the TRIMs (Chauhan et al., 2016; Priglinger et al., 2013).

No core ER proteins or enzymes required for N-linked glycosylation upstream of the Golgi were identified in the screen. Furthermore, not all subunits of the COG family were identified. sgRNAs targeting Gal-3 itself were also not enriched in the screen. Analysis of the control unsorted population shows that the screen was not saturating and 7% of the sgRNA in the library were not present and around 20% showed a coverage of less than 200 cells/sgRNA (data not shown). Five sgRNAs targeting Gal-3 were efficiently represented, yet these cells were not enriched during the screen. This may indicate that these guides were not effective at targeting Gal-3 or Gal-3 deletion is lethal or decreased cell growth Another explanation for the lack of Gal-3 sgRNA enrichment is that Gal-3 secreted by other surrounding cells is able to bind to the surface of Gal-3 null cells, masking the effect of the knockout in our FACS.
assay. This scenario could also affect other knockout cells, where the sgRNA targets key regulators of Gal-3 secretion but glycosylated binding partners on the cell surface are unaffected. However, some of the hits identified in the screen such as TRIM34, TRIM5, ARHGAP30 and ARHGAP9 are not known to regulate the glycosylation pathway. Therefore, it remains unclear why Gal-3 was not enriched in this screen.

Additionally, we did not identify genes previously linked to unconventional secretion such as LC3, GABARAP, GRASP55 and ESCRT components (table S1) (for review, (Nickel & Rabouille, 2009; Rabouille, 2017). To further confirm that autophagy, the GRASP55 and the ESCRT pathways do not regulate cell surface localization of Gal-3, we used LC3 and GABARAP knockout cells (figure S2A), GRASP55 esiRNA (figure S2B) and a Vps4 dominant negative mutant (figure S2C). In all cases the cell surface expression of Gal-3 remained unaffected, further verifying the absence of these genes in the CRISPR/Cas9 forward genetic screen.

**N-linked glycosylation is required for cell surface binding but not galectin secretion**

Since it remains controversial whether glycosylation is required for galectin trafficking to the cell surface, we determined if defective N-linked glycosylation decreased Gal-3 trafficking to the cell surface or if N-linked glycoproteins are simply required for Gal-3 cell surface binding. Tunicamycin blocks the transfer of N-acetylglucosamine-1-phosphate from UDP-N-acetylglucosamine to dolichol phosphate, the first step in N-linked glycosylation (figure 2A) and was used to inhibit glycosylation in sHeLa cells. Cells were treated with increasing concentrations of tunicamycin to inhibit N-linked glycosylation and the level of cell surface Gal-3 was assessed by flow cytometry. Cell surface Gal-3 decreased as the concentration of tunicamycin increased (figure 2B). Propidium iodide was used to measure cell viability and cells remained viable at all tunicamycin concentrations (figure 2B, right). In agreement with the results of the CRISPR screen, this shows that a reduction in N-linked glycosylation (and thus complex glycans at the cell surface) decreases cell surface Gal-3.

To investigate whether N-linked glycosylation is required for transport of Gal-3 from the cytosol to the extracellular space, the supernatant of sHeLa cells treated with tunicamycin was analysed by western blotting. In this assay, if N-linked glycosylation is indeed required for Gal-3 transport there should be a reduction in the level of Gal-3 in the supernatant
compared to untreated cells. Conversely, if N-linked glycosylation is only required for cell surface binding and not for secretion, there should be an increase in free Gal-3 measured in the supernatant. Western blotting showed a concentration dependent increase of Gal-3 in the supernatant after tunicamycin treatment (figure 2C). A similar trend was observed for Gal-1 (figure 2C, left). The effectiveness of tunicamycin treatment was confirmed by assessing the relative expression of the ER resident protein BiP (GRP78), where increased expression indicates ER stress (figure 2C). Actin and Annexin A2 were used as negative controls, with low levels detectable in the supernatant upon tunicamycin treatment (figure 2C). These results support the suggestion that Gal-3 and Gal-1 require N-linked glycans to bind to the cell surface (Patnaik et al., 2006). These data also suggest that secretion of galectins from the cytosol to the extracellular space is independent of N-linked glycosylation.

N-linked glycan maturation mediated by MGAT1 and SLC35A2 is required for Gal-3 cell surface binding but not secretion

The use of tunicamycin to block N-linked glycosylation provides proof of principle but there may be confounding factors due to off target effects. Therefore, to validate the findings of the CRISPR screen and investigate the role of N-linked glycan maturation we targeted MGAT1 and SLC35A2; two genes that were highly enriched in the screen and are known to be specifically required for N-linked glycosylation (figure 1C and 1D). In the cis-Golgi MGAT1 adds N-acetylglucosamine to the sugar backbone of glycoproteins, initiating complex N-linked glycosylation (figure 1D). SLC35A2 acts later in the trans-Golgi, transporting UDP-galactose into the trans-Golgi network for addition onto glycoproteins (figure 1D).

We generated MGAT1 and SLC35A2 CRISPR knockout cell lines using guide RNAs from an independent CRISPR/Cas9 library (Wang et al., 2015). This provides an additional control for off-target effects as the guide RNAs differed from those used in our original CRISPR screen. Single cell cloning, using FACS, was carried out to obtain knockout clones for MGAT1 and SLC35A2 (figure S3). To evaluate the presence of CRISPR induced mutations in either MGAT1 or SLC35A2 genes, the targeted region of the gene was amplified and sequenced. Alignments and Tracking of Indels by Decomposition (TIDE) analysis confirmed that MGAT1 and SCL35A2 contain CRISPR induced insertions and deletions (figure S3) (Brinkman, Chen, Amendola, & van Steensel, 2014). MGAT1 and SLC35A2 clones contained a combination of homozygous and compound heterozygous
deletions likely to disrupt gene function (figure S3). As a positive control, additional MGAT1 and SLC35A2 clones that expressed cell surface Gal-3 to a similar level as untargeted cells (Gal-3 positive) were isolated; these contained no insertions or deletions in the targeted region (figure S3).

CRISPR induced deletions led to a loss of target protein expression in both MGAT1 clones and SLC35A2 clones, assessed by western blotting (figure 3A). MGAT1 and SLC35A2 protein levels are similar to wild type in the Gal-3 positive clones (figure 3A). MGAT1 and SLC35A2 are both essential for N-linked glycosylation, so defective glycosylation would be expected on all N-linked glycoproteins. To assess this, lysosomal associated membrane protein-2 (LAMP-2) glycoforms were analysed by western blotting. MGAT1 and SLC35A2 deficient clones expressed a lower molecular weight form of LAMP-2 compared to wild type and Gal-3 positive sHeLa cells (Figure 3A). This indicates that there are fewer mature N-linked glycans added to LAMP-2 when MGAT1 or SLC35A2 are absent.

To confirm that the loss of MGAT1 and SLC35A2 leads to a decrease in the expression of Gal-3 on the cell surface, as identified in the initial CRISPR screen, we assessed cell surface Gal-3 using flow cytometry. Gal-3 positive clones expressing MGAT1 and SLC35A2 were indeed positive for Gal-3 at a comparable level to wild type sHeLa (figure 3B). Likewise, MGAT1 and SLC35A2 deficient clones obtained from the Gal-3 negative population showed a marked reduction in the expression of Gal-3 (figure 3B). Therefore, the Gal-3 negative phenotype seen by flow cytometry can be attributed to CRISPR-mediated knockout of MGAT1 and SLC35A2, further validating the original CRISPR screen.

To assess whether loss of MGAT1 or SLC35A2 impacts the transport of Gal-3 from the cytosol to the extracellular space, we analysed Gal-3 secretion by western blotting. Our results show that in both MGAT1 and SLC35A2 deficient cells, Gal-3 is readily detected in the extracellular medium (figure 3C). Furthermore, in MGAT1 and SLC35A2 deficient cells there was an increase in the relative amount of Gal-3 in the supernatant compared to the wild type sHeLa control (figure 3C). This was not seen in the Gal-3 positive wild type clones, which remained similar to wild type sHeLa (figure 3C). Gal-1 also showed a similar trend in SLC35A2 knockout cells (figure S3). Therefore, a lack of N-linked glycosylation due to MGAT1 or SLC35A2 deficiency leads to reduced galectin binding to the cell surface and an increase in galectin in the supernatant. This is indicative of a binding defect and not a reduction in secretion.
**CHO glycosylation mutants also efficiently secrete galectins**

To further assess the role of N-linked glycosylation in the transport of galectins to the cell surface and their secretion, several well characterized CHO cell lines with glycosylation defects were used to validate our data (Stanley, 1989). These include an MGAT1 loss of function mutant (Lec1), an SLC35A2 loss of function mutant (Lec8) and an MGAT1 and SLC35A2 loss of function double mutant (Lec3.2.8.1) (Stanley, 1989). The aberrations in the N-linked glycans produced from each cell line are depicted in figure 4A.

These cell lines were previously used to analyze galectin-glycan binding specificity, demonstrating that N-linked glycans are the major ligand for Gal-1, -3 and -8 binding at the cell surface (Patnaik & Stanley, 2006). These mutant CHO lines were used here to further assess Gal-3 and Gal-1 cell surface binding and secretion. Flow cytometry analysis of Gal-3 expression on the surface of CHO cells showed that MGAT1 (Lec1) and SLC35A2 (Lec8) single loss of function mutant lines, as well as the MGAT1/SLC35A2 (Lec3.2.8.1) double mutant line all exhibited a decrease in the level of Gal-3 detectable on the cell surface compared to the wild type (Pro5) (figure 4A). This phenotype was reversed in an MGAT1 rescue cell line, confirming that the loss of Gal-3 on the surface is due to the loss of function mutation in the MGAT1 gene (figure 4B) (Chen & Stanley, 2003; Kumar & Stanley, 1989). Western blotting analysis showed that Gal-3 was secreted by MGAT1 (Lec1) and SLC35A2 (Lec8) loss of function cells as expected (figure 4C). Furthermore, the level of Gal-3 detectable in the medium is substantially higher than the wild type (Pro5) CHO and MGAT1 rescue cell lines (figure 4C). This was also evident when Gal-1 secretion was assessed (figure 4C). These data are consistent with results obtained in sHeLa lines and further confirms that N-linked glycosylation is not required for Gal-3 secretion.

**Secreted Gal-3 is primarily free and not packaged into extracellular vesicles**

Thus far, we have shown that N-linked glycan maturation is not required for the transport of Gal-3 from the cytosol to the extracellular space and is a regulatory element that retains galectins at the cell surface. Next, we set out to investigate whether secreted Gal-3 is free in the medium or packaged into EVs. There is conflicting data in the literature as to whether galectins are secreted via EVs (Cooper & Barondes, 1990; Mehul & Hughes, 1997; Sato et al., 1993; Seelenmeyer et al., 2008). To investigate this, the medium from wild type,
MGAT1 or SCL35A2 deficient cells was collected and subjected to differential centrifugation. Briefly, cells were removed at 300g, then the cell debris was removed at 3000g and EVs pelleted at 100,000g. The supernatant and EV pellets were separated after centrifugation at 100,000g and each assessed for Gal-3 by western blot. The data show similar levels of Gal-3 in the medium after removing EVs at 100,000g, indicating that the majority of the secreted Gal-3 is free and not packaged in vesicles (figure 5A and B). Gal-3 is detectable in the 100,000g EV pellet of all cell lines, although the levels were somewhat variable, and there was a small increase in the amount of both actin and Gal-3 detected in the EV pellets from MGAT1 deficient clones (figure 5A and B). It is important to note that the EV pellets are 50x concentrated compared to the supernatant samples (figure 5A and B). To assess the composition of the 100,000g pellet further, we analysed the tetraspanin CD63 which is known to be enriched in exosomes (Escola et al., 1998). The 100,000g pellet was CD63 positive and therefore contained some exosomes (figure 5A and B). Due to impaired glycosylation CD63 runs as a smaller form in the MGAT1 and SLC35A2 deficient EVs (figure 5A and B). The lack of glycosylation on CD63 seems to affect the antibody detection and the naked non-glycosylated form it detected better than the glycosylated form. Therefore, it is difficult to comment on the relative levels of CD63 in the EV pellets of the MGAT1 and SLC35A2 compared to the wild type controls. However, we believe that the lack of MGAT1 or SLC35A2 does not affect the formation or level of EVs.

We also assessed whether Gal-3 secreted from CHO MGAT1 (Lec1), SLC35A2 (Lec8) and MGAT1/SLC35A2 double (Lec3.2.8.1) mutant cell lines is also free and not packaged into EVs. In agreement with the sHeLa MGAT1 and SLC35A2 deficient cells, the levels of Gal-3 secreted from the CHO MGAT1 (Lec1), SLC35A2 (Lec8) and MGAT1/SLC35A2 double (Lec3.2.8.1) mutant lines remained unchanged after a 100,000g centrifugation step (figure 5C). There was a small increase in the level of Gal-3 and actin detectable in the EV pellets of MGAT1 (Lec1), SLC35A2 (Lec8) and MAGT1/SLC35A2 double (Lec3.2.8.1) mutants compared to wild type (Pro5) and rescue lines (figure 5C). This may also be reflected in the MGAT1 deficient cells but is not the case for SLC35A2 which was more variable (figure 5A and B). Therefore, any differences in level of EVs secreted is trivial and is unlikely to significantly contribute to the levels of secreted Gal-3. Due to differences in the species of the cells we were unable to evaluate CD63 in the EV pellets of CHO. Together these results show that Gal-3 associated with EVs comprises a small
proportion of the total secreted Gal-3 and therefore cannot be the primary route for trafficking outside the cell.

N-linked glycoproteins are required for the recruitment of intracellular Gal-3 to damaged lysosomal membranes

Gal-3 has important roles in regulating cell death and immunity, and is recruited to endolysosomes, lysosomes and phagosomes in response to induced organelle damage and damage due to bacterial infection (Aits et al., 2015; Feeley et al., 2017; Maejima et al., 2013; Paz et al., 2010). In addition, Gal-3 interacts with TRIM16 to coordinate autophagy to protect against cell damage and bacterial invasion (Chauhan et al., 2016). Recruitment to lysosomes or Shigella disrupted phagosomes is dependent on Gal-3 binding to N-linked glycans, as shown using a Gal-3 CRD mutant and CHO MGAT1 mutant (Lec1) cells respectively (Aits et al., 2015; Paz et al., 2010). Therefore, N-linked glycans are not only important for cell surface localisation of Gal-3 but are also central for the recruitment of Gal-3 to damaged lysosomes. To further characterise our MGAT1 and SLC35A2 deficient sHeLa cell lines, we assessed the ability of Gal-3 to redistribute from the cytosol to the membrane of leaky lysosomes (Maejima et al., 2013). To do so we expressed green fluorescent protein (GFP) fused to Gal-3 in wild type, MGAT1 and SLC35A2 deficient sHeLa lines. All cell lines were then treated with L-Leucyl-L-Leucine methyl ester (LLOMe) to induce lysosomal leakiness and we assessed the recruitment of GFP-Gal-3 to the site of damage by immunofluorescence (Maejima, Takahashi et al. 2013). In wild type cells, GFP-Gal-3 is efficiently redistributed from the cytosol to the site of lysosomal damage, colocalizing with LAMP-2 positive puncta (figure 6A). However, in MGAT1 and SLC35A2 deficient cells the recruitment of GFP-Gal-3 to LAMP-2 positive damaged lysosomes are reduced (figure 6A). We also assessed recruitment of LC3, as damage to lysosomes should initiate autophagy to degrade the dysfunctional organelle (Maejima et al., 2013). As expected, in wild type cells treated with LLOMe GFP-Gal-3 positive puncta were also mRFP-LC3 positive (figure 6B). In the MGAT1 and SLC35A2 deficient cells recruitment of GFP-Gal-3 to mRFP-LC3 positive damaged lysosomes is impaired (figure 6B). This further confirms that N-linked glycan maturation is required for the recruitment of Gal-3 to damaged lysosomes and autophagosomes, essential for cellular homeostasis and defense.


Discussion

Cell surface expression of galectins is essential for cellular homeostasis. Despite having important functions in the extracellular space, the mechanism of galectin secretion remains unclear. Galectins do not enter the classical secretory pathway, as they do not contain a signal peptide and their secretion is not affected by drugs that block this pathway (Hughes, 1999). Therefore, they must exit the cell though an unknown unconventional protein trafficking pathway. Currently there is limited data available to explain the mechanisms of galectin trafficking from the cytosol to the extracellular space and current theories are controversial. Here we applied a genome-wide CRISPR screen using the GeCKO v2 library to identify regulators of Gal-3 cell surface localisation. Following mutagenesis and enriching for cells with reduced Gal-3 expression at the cell surface, many genes coding for glycoproteins or proteins required for N-linked gycan maturation were identified. While this screen returned many important regulators of Gal-3 it is apparent that the screen was not saturating. As discussed in the results section, sequencing data from the control unsorted population shows that the screen was not saturating. However, five sgRNAs targeting Gal-3 were efficiently represented in the control unsorted population, yet these cells were not enriched during sorting. One explanation for this is that there is free Gal-3 in the medium, secreted by surrounding cells, that binds to the surface of Gal-3 deficient cells masking their Gal-3 negative phenotype. This could also mask other important hits where secretion of Gal-3 is impaired but glycosylation is normal. Unfortunately, we were not able to assess the levels of Gal-3 in the medium and therefore do not know if this explains the lack of Gal-3 sgRNA enrichment. Moreover, there are hits identified in this screen that are not known to regulate glycosylation (such as TRIM34, TRIM5, ARHGAP30 and ARHGAP9), which should also be masked in this scenario. Additionally, we did not detect any ER proteins required for glycosylation, upstream of the Golgi, which is somewhat surprising. Loss of these proteins may be lethal or decrease cell proliferation. It is also important to note that the most significantly enriched genes identified by the screen may not be those most important for mediating Gal-3 surface localisation, it may simply be that they survive well and are therefore enriched better than others.

Although the screen was not saturating, the results obtained here are consistent with the literature as Gal-3 is known to bind to N-linked glycans present on the cell surface (Patnaik et al., 2006). This is also consistent with the notion that Gal-3 requires N-linked glycans to facilitate trafficking from the cytosol to the cell surface (Seelenmeyer et al., 2005).
However, this is controversial and it was important to establish whether glycoproteins carrying N-linked sugar moieties are required for transport of Gal-3 from the cytosol to the extracellular space. Using tunicamycin and two different MGAT1 and SLC35A2 mutant cell lines we demonstrate that Gal-3 cell surface binding is dependent on the expression of complex N-linked glycans, however, Gal-3 is efficiently secreted in the absence of N-linked glycans. The secretion of both Gal-3 and Gal-1 was unperturbed in the absence of N-linked glycosylation, clearly demonstrating that their secretion is independent of both the classical secretory pathway and any pathway requiring complex glycoproteins and lipids for transport.

The role of EVs in galectin secretion has been controversial, with conflicting reports in the literature (Cooper & Barondes, 1990; Mehul & Hughes, 1997; Sato et al., 1993; Seelenmeyer et al., 2008). Here, we demonstrate that transport of Gal-3 from the cytosol to the extracellular space is not primarily mediated by EVs in sHeLa and CHO cell lines. Due to the increased levels of Gal-3 detectable in the medium, MGAT1 and SLC35A2 deficient cells provide an excellent system for assessing whether extracellular Gal-3 is packaged into EVs. Using differential centrifugation, we show that the vast majority of Gal-3 detected in the medium is free and soluble, indicating Gal-3 is not packaged into extracellular vesicles. These data support an EV independent pathway for Gal-3 trafficking to the cell surface and secretion into the extracellular space.

It has previously been shown that Gal-3 is redistributed from the cytosol to glycoproteins on the luminal membrane of damaged endolysosomes/phagosomes (Aits et al., 2015; Feeley et al., 2017; Maejima et al., 2013; Paz et al., 2010). Once associated with the membrane of the damaged organelle, Gal-3 stimulates autophagy to clear the threat (Maejima et al., 2013). Furthermore, it has been shown that Gal-3 is recruited to *Shigella* containing phagosomes in wild type CHO cells but not MGAT1 (Lec1) mutant CHO cells (Paz et al., 2010). Given these previous data we tested the MGAT1 and SLC35A2 deficient sHeLa cells in this context. As expected, Gal-3 recruitment to damaged lysosomes is impaired in the MGAT1 and SLC35A2 cell lines. These data, shown by us and others, may explain why people with congenital disorders of glycosylation (CDG) suffer from recurrent infections, reviewed (Albahri, 2015; Grunewald, Matthijs, & Jaeken, 2002; Monticelli, Ferro, Jaeken, Dos Reis Ferreira, & Videira, 2016). CDG are rare genetic disorders where glycosylation of multiple proteins are deficient or defective due to mutations in the glycosylation pathway; these mutations can occur in COG1, MGAT1 and SLC35A2 genes among many others (Albahri, 2015; Grunewald et al., 2002). CDG cause a range multiple organ malfunctions, in
almost all cases the nervous system is affected and symptoms include developmental
disabilities, ataxia hypotonia, hyporeflexia and immunological defects (Albahri, 2015;
Grunewald et al., 2002; Monticelli et al., 2016). It is becoming increasingly apparent that
patients with immunological defects are more likely to have mutations in resident ER and
Golgi enzymes (Monticelli et al., 2016). Consistent with this, our data and previous data from
Paz and colleagues suggest that patients with certain forms of CDG could have a reduced
ability to sense bacterial or viral entry in the cytosol due to a lack of galectin recruitment to
the site of infection (Paz et al., 2010).

Together these data demonstrate that galectin cell surface binding and secretion are
two distinct events. This is consistent with previous studies, which have shown that Gal-3
secretion is unaffected by disruptions in the secretory pathway (Cho & Cummings, 1995;
Lindstedt et al., 1993; Sato et al., 1993). Exactly which domains or sequences are essential
for mediating galectin secretion are also controversial. It has been shown that the flexible N-
terminial domain on Gal-3 is important for secretion, however, this flexible N-terminal
domain is absent in other galectins (Menon & Hughes, 1999). Therefore, if there is a common
unconventional secretory pathway utilized by the galectin family, it would be somewhat
surprising if this was located in the only domain that is not conserved across the galectin
family. In contrast, other studies have found that the CRD is essential for the effective
secretion of Gal-1 (Seelenmeyer et al., 2005). However, in our hands the CRD mutant Gal-3
(R186S), which is unable to bind GlcNAc, did not show any defects in Gal-3 secretion
compared to the wild type (figure S5)(Salomonsson et al., 2010). It is possible that there are
differences in the requirements for secretion between galectin family members, but this
would be very surprising as the galectins are highly similar and common transport
mechanism would be expected.

Regardless of the exact mechanism, it may be expected that galectins are not secreted
via the conventional secretory pathway as their ligand (complex carbohydrates) is a major
component of the lumen of the ER and Golgi. If galectins had to move through the ER and
Golgi they would come into contact with their ligand, bind and potentially interrupt the
movement of other proteins through the secretory pathway. Therefore, having a separate
pathway for trafficking galectins to the cell surface is an excellent way of ensuring that they
only meet their ligands where required.

Finally, hundreds of genetic disorders that result from deficiencies in different
glycosylation pathways have been described, including several neurological diseases such as
autism, epilepsy and CDG (Freeze, Eklund, Ng, & Patterson, 2015). Additionally, cancer cells are known to deeply alter the glycosylation pathway inducing hypo- or hyper-glycosylation (Pinho & Reis, 2015). As such, it would be interesting to study whether the alterations in several signaling pathways described in these diseases are associated with a dysregulation of cell surface galectins given the important role of galectins in signal transduction and cell to cell interactions.

Materials and methods

Cell culture

Suspension HeLa cells were cultured in DMEM D6546 (Molecular Probes) plus 10% fetal bovine serum (FBS), 2 mM L-glutamine and 100 U ml⁻¹ penicillin/streptomycin in 5% CO₂ at 37°C. LC3 and GABARAP knockout HeLa cells were cultured as described (Nguyen et al., 2016). Lec cells (CHO), obtained from Pamela Stanley (Albert Einstein College of Medicine), were cultured in MEM alpha, nucleosides (Molecular Probes, 22571038) plus 10% FBS and 100 U ml⁻¹ penicillin/streptomycin in 5% CO₂ at 37°C.

Antibodies and reagents

Antibodies: rat polyclonal anti-Galectin-3 (Biolegend; 125408; WB: 1/2,000), rat polyclonal anti-Galectin-3 conjugated to Alexa Fluor647 (Biolegend; 125402; FC: 1/100), rabbit polyclonal anti-Galectin-1 (a generous gift from Walter Nickel, Heidelberg University; WB: 1/500), mouse monoclonal anti-Annexin A2 (BD Biosciences; 610071; WB: 1/1,000), rabbit polyclonal anti-Actin (Sigma; A2066; WB: 1/2,000), rabbit polyclonal anti-BiP (Abcam; ab21685: WB: 1/1,000), mouse monoclonal anti-LAMP2 (Biolegend; 354302; WB: 1/1,000; IF: 1/100), rabbit polyclonal anti-SLC35A2 (Cambridge Bioscience; HPA036087; WB: 1/500), rabbit polyclonal anti-MGAT1 (Abcam; ab180578; WB: 1/1,000), mouse monoclonal anti-human CD63 (Thermo Fisher Scientific; 10628D; WB: 1:500), rabbit polyclonal anti-GFP (Clontech; 632592; WB: 1/2,000), rabbit polyclonal anti-LC3B (Novus Biologicals; NB100-2220; WB: 1/2,000), rabbit polyclonal anti-GABARAP (Abgent; AP1821a; WB: 1/1,000), monoclonal anti-CD29 (BD Biosciences; Clone 18/CD29; WB: 1/2,000) and rabbit polyclonal anti-GRASP55 (Proteintech; 10598-1-AP; WB: 1/1,000).
Reagents: tunicamycin (New England Biolabs; 12819), L-Leucyl-L-leucine methyl ester (Sigma-Aldrich; L7393), propidium iodide solution (Biolegend; 421301), QuickExtract DNA extraction solution (Epicenter; QE0905T), Herculase II fusion DNA polymerase (Agilent; 600675). Oligonucleotides for MGAT1 and SLC35A2 CRISPR targeting and sequencing were synthesized from Sigma-Aldrich (table S2). MISSION esiRNA against GRASP55 was from Sigma-Aldrich (EHU056901).

Plasmids

pSpCas9(BB)-2A-GFP (PX458) was a gift from Feng Zhang (Addgene plasmid # 48138), Galectin-3 vector, pEGFP-hGal3, and mRFP-LC3 were a gift from Tamotsu Yoshimori (Addgene plasmid # 73080 and # 21075 respectively) (Maejima et al., 2013), LentiCas9-Blast was a gift from Feng Zhang (Addgene plasmid # 52962), Vps4 wild type and EQ mutant were a gift from Colin Crump (Crump, Yates, & Minson, 2007).

CRISPR screen

The Cas9 nuclease was stably expressed in suspension HeLa cells by lentiviral transduction (Sanjana, Shalem, & Zhang, 2014). Approximately 1x10^8 cells were then transduced with the GeCKO v2 sgRNA library (Addgene cat#1000000047, kindly deposited by Prof. Feng Zhang (Shalem et al., 2014)) at a multiplicity of infection of around 0.2. Untransduced cells were removed from the library through puromycin selection (1 mg ml^{-1}) commencing 48 h after transduction. Rare cells that had lost cell surface Galectin-3 were then enriched by sequential rounds of FACS, with the first sort taking place 7 days after transduction with the sgRNA library and the second sort a further 14 days later. Genomic DNA was extracted (Puregene Core Kit A, Qiagen) from both the sorted cells and an unselected pool of mutagenized cells. sgRNA sequences were amplified by two rounds of PCR, with the second round primers containing the necessary adaptors for Illumina sequencing (table S2). Sequencing was carried out using a 50 bp single-end read on an Illumina HiSeq2500 instrument using a custom primer binding immediately upstream of the 20 bp variable segment of the sgRNA. The 3’ end of the resulting reads were trimmed of the constant portion of the sgRNA, and then mapped to an index of all of the sgRNA sequences in the GeCKO v2 library using Bowtie 2.
The resulting sgRNA count tables were then analyzed using the RSA algorithm using the default settings (Rivest, Shamir, & Adleman, 1978).

Bioinformatics pathway analysis

The first 200 hits identified in the CRISPR screen were loaded to the analysis wizard of the DAVID Bioinformatics Resources 6.8 to perform a pathway analysis (Huang da et al., 2009a, 2009b). According to the algorithm only those genes with known function are included in the pathway analysis and hence not all genes will appear in the tabulated results (table 1).

CRISPR-mediated gene disruption

For CRISPR/Cas9-mediated gene disruption, oligonucleotides (Sigma-Aldrich; table S2) for top and bottom strands of the sgRNA were annealed, and then cloned into the Cas9 expression vector pSpCas9(BB)-2A-GFP (PX458) (Addgene plasmid # 48138, kindly deposited by Feng Zhang) as previously described (Ran et al., 2013). Transfected cells were sorted for GFP fluorescence and clones were isolated by FACS based on a loss of cell surface Galectin-3. Gene disruption was verified by collecting genomic DNA from clonal lines with QuickExtract DNA extraction solution and amplifying the CRISPR/Cas9 targeted region with primers flanking at least 200 base pairs either side of the expected cut site (table S2). PCR products were sequenced by Sanger sequencing. Insertions and deletions analysed by sequence alignment and Tracking of Indels by DEcomposition (TIDE) (Brinkman et al., 2014). In addition to using the TIDE web tool, the R code was kindly provided by Prof van Steensel, to analyse clones containing deletions larger than 50 base pairs.

Flow cytometry

Cells were washed once with serum-free medium, incubated at 4°C for 30 min with an anti-Galectin-3 antibody conjugated to Alexa Fluor647, washed again and analysed on a FACSCalibur (BD) equipped with lasers providing 488nm and 633nm excitation sources. Alexa Fluor647 Fluorescence was detected in FL4 detector (661/16 BP). For sorting, cells were immunostained as above and FACS was carried on an Influx cell sorter (BD) or Aria-
Fusions (BD) equipped with lasers providing 488 nm and 640 nm excitation sources. Alexa Fluor647 Fluorescence was detected in 670/30 BP detector on Influx and the Aria Fusion.

**Fluorescence and immunofluorescence microscopy**

For immunofluorescence microscopy, cells were cultured on coverslips, fixed with 4% paraformaldehyde in PBS for 5 min and permeabilized with 0.1% Triton X100 in PBS for 5 min. Coverslips were incubated with primary antibodies for 2 h, washed three times with PBS, and incubated with secondary antibodies for 30 min. Samples were mounted using ProLong Gold antifade reagent with DAPI (4,6-diamidino-2-phenylindole; Invitrogen) and observed using a Leica SP8 laser confocal microscope.

**Immunoblotting**

All samples were resolved by 12% SDS-polyacrylamide gel electrophoresis (PAGE) and transferred to polyvinylidene difluoride membranes for blotting. Membranes were blocked with 5% (w/v) skim milk powder in PBS containing 0.1% Tween-20 (PBS-Tween) for 30 min at room temperature. Membranes were then probed with an appropriate dilution of primary antibody overnight at 4°C. Membranes were washed three times in PBS-Tween before incubation in diluted secondary antibody for 1 h at room temperature. Membranes were washed as before and developed with ECL (Amersham ECL Western Blotting Detection Reagent RPN2106 for the detection of proteins in the cell lysates or Cyanagen, Westar XLS100 for the detection of proteins in the secreted fractions) using a Bio Rad ChemiDoc XRS system. Membranes were stripped with Restore plus (ThermoFisher Scientific, 46430) as per manufactures’ instructions.

**Secretion assay**

To measure the secretion of galectins, cells were washed with serum-free medium and incubated for 24 h for sHeLa or 48 h for CHO (Lec). For sHeLa, serum-free medium was DMEM plus 2 mM L-Glutamine. For CHO (Lec), serum-free medium was EX-CELL® 325 PF CHO (Sigma-Aldrich, C985Z18). Cell supernatants were then collected, centrifuged at
300 g to remove potential remaining cells, either filtered at 0.22 µm or centrifuged at 3000 g to remove cell debris, mixed with sample buffer (50 mM Tris-HCl pH 6.8, 2% SDS (w/v), 0.1% Bromophenol Blue, 10% Glycerol and 100 mM DTT) and boiled at 100°C for 5 min. Cell pellets were lysed in lysis buffer (20 mM Tris-HCl pH 6.8, 137 mM NaCl, 1 mM EDTA, 1% Triton X-100 and 10% Glycerol) at 4°C for 10 min, insoluble material removed by centrifugation at 10,000 g for 10 min 4°C. Sample buffer was added and cell lysate were samples boiled added (as above). Cell lysates and cell supernatants were then subjected to SDS-PAGE. Densitometry was performed in Image J and the difference in the levels of secreted Gal-3 were calculated in each cell line using the following equation: (Gal-3 in supernatant/Gal-3 in lysate). These values were then used to calculate the fold change relative to the control cells.

**Removal of extracellular vesicles**

Cells were processed as described for the secretion assay except after the 3,000g centrifugation step the medium was collected and centrifuged at 100,000 g for 60 min at 4°C. After each centrifugation step a sample of the medium was collected for western blotting. The extracellular vesicle pellet was resuspended in a small volume of non-reducing sample buffer (50 mM Tris-HCl pH 6.8, 2% SDS (w/v), 0.1% Bromophenol Blue, and 10% Glycerol). Half of the EV pellet sample was taken and DTT added to achieve a final concentration of 100 mM. All samples were boiled and resolved by SDS-PAGE. The entire concentrated EV pellet sample was loaded on two gels (reduced and non-reduced) for each sample due to the small scale of the assay. Therefore the EV pellet is 50x more concentrated than the equivalent supernatant.

**Statistical analysis**

Significance levels for comparisons between groups were determined with a two sample Students t- test.
**Author contributions**

S.E.S., S.J.P. and K.M. performed all the experiments in the laboratory of K.M., except for the preparation of the CRISPR lentiviral library, the lentivirus infection and the identification of the hits, which was performed by S.A.M. in the laboratory of P.J.L. A.P.H. and N.S. have conducted preliminary experiments to optimise the sorting protocol, and N.S. performed cell sorting in the NIHR Cambridge BRC Cell Phenotyping Hub under the direction of A.P.H. S.E.S. and K.M. wrote the paper with comments from all the authors.

**Acknowledgements**

We thank Walter Nickel for Galectin-1 antibody, Michael D’Angelo for his help and expertise with CRISPR/Cas9 INDEL analysis, Bas van Steensel for providing the TIDE R code, Matt Castle for R code expertise, Nuno Rocha for his help with CRISPR cloning method, Pamela Stanley for Lec CHO cell lines, Feng Zhang for CRISPR library and px458 vector, Tamotsu Yoshimori for pEGFP-Galectin3 and pmRFP-LC3, Michael Lazarou for the LC3 and GABARAP knockout cells, Colin Crump for the Vps4 vectors.

**Funding**

This work has received support from a Wellcome Trust Strategic Award [100574/Z/12/Z] and MRC Metabolic Diseases Unit [MRC_MC_UU_12012/5] for SS and KM, a Wellcome Trust Principal Research Fellowship to PJL (101835/Z/13/Z), a Wellcome Trust PhD studentship to SAM and SJP, and support from the National Institute for Health Research (Cambridge Biomedical Research Centre/ BioResource for NS and APH.

**Competing interests**

The authors declare no competing financial interests.
References


21


**Figure legends**

**Figure 1.** A CRISPR/Cas9-mediated genetic screen identifies genes required for cell surface localization of Gal-3.

A. Schematic view of the CRISPR/Cas9 screen in suspension HeLa (sHeLa) cells to identify genes required for Gal-3 cell surface localisation. Cells were transduced with a lentiviral sgRNA library (sgRNA transduction indicated by colors in the nucleus) and cells that were successfully transduced were selected for with puromycin. After selection, the population was split into two, one half was sorted by FACS to enrich for cells that have less Gal-3 on the surface (Gal-3 is represented by small orange shapes on the cell surface) and the other was not sorted to represent the entire library. After two rounds of enrichment, the DNA from both the enriched population and the unsorted library was harvested and enriched sgRNAs were identified by sequencing. Targeted genes were then plotted according to their relative enrichment.

B. CRISPR-mediated mutagenesis was performed on sHeLa cells using the GeCKO v2 sgRNA library, and rare cells with decreased surface Gal-3 expression were selected by two
sequential rounds of FACS. Cell surface Gal-3 was measured on live cells using an anti-Gal-3 antibody conjugated to Alexa Fluor647.

C. Plot illustrating the hits from the CRISPR screen. The RSA algorithm was used to identify the significantly enriched genes targeted in the selected cells. The most significantly enriched genes are labelled.

D. Schematic view of the N-linked glycosylation pathway within the Golgi. Genes identified to be important for Gal-3 surface localisation by the CRISPR screen are highlighted in red, and those chosen for further study (MAGT1 and SLC35A2) are shown in bold.

**Figure 2. Tunicamycin decreases cell surface Gal-3 while increasing the level of Gal-3 in the medium.**

A. Schematic representation of tunicamycin inhibition of N-linked glycosylation. Tunicamycin blocks the transfer of N-acetylglucosamine-1-phosphate from UPD-N-acetylglucosamine to dolichol phosphate, the first step in N-linked glycosylation.

B. Tunicamycin reduces cell surface localization of Gal-3. sHeLa cells were treated with increasing concentrations of tunicamycin diluted in serum-free medium for 24 h. Cell surface Gal-3 was measured on live cells using an anti-Gal-3 antibody conjugated to Alexa Fluor647, cell viability was also assessed by flow cytometry using propidium iodide. Unstained cells are shown in grey. Quantification is shown on the right. Error bars represent ±s.e.m. from biological replicates (n = 3); * p<0.05 using a two sample Students t- test comparing each tunicamycin concentration to untreated cells.

C. Tunicamycin increases the levels of Gal-3 in the culture supernatant. Western blotting analysis of cell lysates and supernatants of sHeLa cells treated with increasing concentrations of tunicamycin (24 h at 37°C in serum-free medium). Note that the tunicamycin treatment was efficient as seen by increased level of BiP and decreased level of CD29. Quantification is shown on the right. Error bars represent ±s.e.m. from biological replicates (n = 3); * p<0.05 using a two sample Students t- test comparing each tunicamycin concentration to untreated cells.
Figure 3. MGAT1 and SLC35A2 knockout abrogates Gal-3 cell surface binding but not secretion.

A. Western blotting analysis of MGAT1 and SLC35A2 deficient sHeLa. Cell lysates were assessed for either MGAT1 or SLC35A2 protein levels after CRISPR/Cas9 targeting and single cell cloning based on Gal-3 surface expression. Lysosomal associated protein 2 (LAMP2) was also assessed to analyse defects in glycosylation and actin was used as a loading control.

B. Cell surface localization of Gal-3 is decreased in MGAT1 and SLC35A2 deficient suspension HeLa cells measured by flow cytometry. Cell surface Gal-3 was measured on live cells using an anti-Gal-3 antibody conjugated to Alexa Fluor647. Gray line: no antibody; black: untransfected; pink: sgMGAT1 positive clone; blue: sgMGAT1 negative clone 1; green: sgMGAT1 negative clone 2. The same respective colours are used for sgSLC35A2 in the lower panels.

C. Gal-3 is secreted from MGAT1 and SLC35A2 deficient sHeLa cells. Wild type, positive control and negative clones for MGAT1 (left) and SLC35A2 (right) cells were incubated in serum-free medium for 24 h and the cells and medium then assessed by western blot. Gal-3 was assessed in the lysate and medium (supernatant), actin was used as a loading control and control for cell lysis. Exposure times are indicated to allow relative comparisons between blots to illustrate the large increase in Gal-3 in the supernatant compared to actin. Quantification for MGAT1 (right; green) and SLC35A2 (left; orange) is shown at the bottom. Error bars represent ±s.e.m. from biological replicates (n = 3); * p<0.05 using a two sample Students t- test comparing each cell line to wild type cells.

Figure 4. MGAT1 and SLC35A2 mutation in CHO Lec cells reduces Gal-3 cell surface binding but does not affect secretion.

A. Gal-3 cell surface localization is decreased in MGAT1 and SLC35A2 mutant CHO lines. Cell surface Gal-3 was measured on live MGAT1 (Lec1), SLC35A2 (Lec8) and double mutant (Lec3.2.1.8) CHO Lec cells compared to wild type (Pro5) cells by flow cytometry using an anti-Gal-3 antibody conjugated to Alexa Fluor647. Gray line: no antibody; dark brown: wild type; red: mutants. Predicted N-linked glycans for each cell line are shown on the histograms. Sugar symbols: purple triangle, fuctose; green circle, mannose; orange circle,
galactose; blue square, N-acetylglucosamine; pink trapezoid, sialic acid. Quantification is shown on the right. Error bars represent ±s.e.m. from biological replicates (n = 3); * p<0.05 using a two sample Students t-test comparing each mutant CHO line to wild type (Pro5) cells.

B. Gal-3 cell surface localization is rescued in MGAT1 rescue CHO Lec cells measured by flow cytometry. Gal-3 was measured as per A. Gray line: no antibody; dark brown: wildtype; red: mutants; purple: rescue. Quantification is shown on the right. Error bars represent ±s.e.m. from biological replicates (n = 3); * p<0.05 using a two sample Students t-test comparing the MGAT1 mutant and rescue lines to wild type (Pro5) cells.

C. Gal-3 is secreted from MGAT1 and SLC35A2 mutant CHO Lec cells. Wild type (Pro5), MGAT1 (Lec1), MGAT1 rescue, SLC35A2 mutant (Lec8) and the double mutant (Lec3.2.8.1) were incubated in EX-CELL® 325 PF CHO for 48 h and cells and medium were assessed by western blot. Gal-3, Gal-1 and actin were analysed in the cell lysates and medium (supernatant). Exposure times are indicated to allow the lysates and supernatants to be compared. Quantification is shown on the right. Error bars represent ±s.e.m. from biological replicates (n = 3); * p<0.05 using a two sample Students t-test comparing each mutant CHO cell line to wild type (Pro5) cells.

Figure 5. Secreted Gal-3 is predominantly soluble and not packaged in extracellular vesicles.

A. Soluble Gal-3 is secreted from MGAT1 deficient sHeLa cells. Wild type, positive control and negative clones for MGAT1 deficient cells were incubated in serum-free medium for 24 h. The cells were collected and lysed whereas the medium was subjected to differential centrifugation at 300g, 3000g and 100,000g. A sample of the medium was collected after each centrifugation step. Gal-3 was assessed in the lysate, the entire 100,000g EV pellet and medium (supernatant). Actin was used as a loading control and control for cell lysis. Exposure times are indicated for comparison. The 100,000g EV pellets were also analysed by western blot for levels of glycosylated and non-glycosylated CD63.
B. Soluble Gal-3 is secreted from SLC35A2 deficient sHeLa cells. Wild type, positive control and negative clones for SLC35A2 deficient cells were incubated in serum-free medium for 24 h. Samples were treated as described in panel A.

C. Secreted Gal-3 from MGAT1 and SLC35A2 mutant CHO Lec cells is soluble. Wild type (Pro5), MGAT1 (Lec1), MGAT1 rescue, SLC35A2 mutant (Lec8) and the double mutant (Lec3.2.8.1) were incubated in EX-CELL® 325 PF CHO for 48 h and cells and medium collected. The cells, 100,000g EV pellet and medium were processed as in A above. Gal-3 and actin were analysed by western blot and exposure times are indicated for comparison. CD63 was not analysed in this experiment as it does not cross-react with hamster CD63.

Figure 6. Recruitment of GFP-Gal3 to damaged lysosomes is reduced in MGAT1 and SLC35A2 deficient cells.

A. Wild type (control), MGAT1 deficient (clone 1) or SLC35A2 deficient (clone 1) sHeLa transiently expressing GFP-Gal-3 for 24 h were treated with 1 mM L-Leucyl-L-Leucine methyl ester (LLOMe) for 3 h. Cells were fixed with PFA, permeabilised with Triton X100 and subjected to immunocytochemistry using an anti-LAMP2 antibody, then processed to confocal microscopy. Bars: 10 um. The intensity of LAMP2 and Gal-3 signals measured using ImageJ in a minimum of 20 cells per condition is shown on the right.

B. Wild type (control), MGAT1 deficient (cl1) or SLC35A2 deficient (cl1) sHeLa transiently expressing GFP-Gal-3 and mRFP-LC3 for 24 h were treated with 1 mM LLOMe for 3 h. Cells were fixed with methanol and processed to confocal microscopy. Bars: 10 um. Colocalization (Pearson’s coefficient) between Gal-3 and LC3 is shown on the right. Error bars represent ±s.e.m. from individual cells (n > 20); * p<0.05 using a two sample Students t-test.
Table 1. Pathway analysis of the 200 most significantly enriched genes identified in the genome-wide CRISPR screen for Gal-3 cell surface localisation.
Figure 1. A CRISPR/Cas9-mediated genetic screen identifies genes required for cell surface localization of Gal-3

A

sgRNA library transduction → Selection → Enrichment → Sequencing and data analysis

- Cas9 expressing cells
- Virus
- Puromycin selection
- Surface stain and FACS for Gal-3 negative cells
- Unsorted library cells
- sgRNA PCR amplification
- Deep sequencing

B

Starting clone
After mutagenesis
After sort 1
After sort 2

Glycine (FL3)

0.1%
0.2%
0.4%
25%

C

Genes ranked alphabetically

COG1
MGAT1
SLC35A9
UNC50
SLC39A9
MAN1A2
SLC35A2

D

Anterograde transport
Retrgrade transport and recycling
Protein
- Manose
- N-acetylgalactosamine
- Fucose
- Galactose
- Sialic acid
To the plasma membrane or extracellular space
Figure 2. Tunicamycin decreases cell surface Gal-3 while increasing the level of Gal-3 in the medium.

A

B

C

- Tunicamycin
- Cell surface Galectin-3 (%)
- Galectin-3 (%)
- Viability (%)

- Tunicamycin (ug/ml)
- 0 0.1 1 5

- Galectin-3 (5s)
- Galectin-1 (20s)
- Actin (20s)
- Annexin A2 (20s)
- BIP (60s)
- CD29 (150s)

- Galectin-3 (5s)
- Galectin-1 (600s)
- Actin (60s)
- Annexin A2 (120s)
- BIP (120s)
- CD29 (600s)
Figure 3. MGAT1 and SLC35A2 knockout abrogates Gal-3 cell surface binding but not secretion.

A

B

C

<table>
<thead>
<tr>
<th></th>
<th>48kDa</th>
<th>35kDa</th>
<th>28kDa</th>
<th>100kDa</th>
<th>75kDa</th>
<th>63kDa</th>
<th>48kDa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild type</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgMGAT1-pos</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgMGAT1-neg-cl1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgMGAT1-neg-cl2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>48kDa</th>
<th>35kDa</th>
<th>28kDa</th>
<th>100kDa</th>
<th>75kDa</th>
<th>63kDa</th>
<th>48kDa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild type</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgSLC35A2-pos</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgSLC35A2-neg-cl1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgSLC35A2-neg-cl2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>48kDa</th>
<th>35kDa</th>
<th>28kDa</th>
<th>100kDa</th>
<th>75kDa</th>
<th>63kDa</th>
<th>48kDa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wild type</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ sgMGAT1-pos</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ sgMGAT1-neg-cl1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ sgMGAT1-neg-cl2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ sgSLC35A2-pos</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ sgSLC35A2-neg-cl1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>+ sgSLC35A2-neg-cl2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Cytosolic fraction
| Galectin-3 (10s) | Actin (30s) |
| Supermatant
| Galectin-3 (5s) | Actin (30s) |

| Cytosolic fraction
| Galectin-3 (20s) | Actin (20s) |
| Supermatant
| Galectin-3 (20s) | Actin (20s) |

Secreted Galactin-3 (fold change compared to wild type)

- *: Significant difference
- NS: Not significant
Figure 4. MGAT1 and SLC35A2 mutation in CHO Lec cells reduces Gal-3 cell surface binding but does not affect secretion.

A

B

C

Cytosolic fraction

Supernatant

Secreted Galactin-3 (fold change compared to wt)
Figure 5. Secreted Gal-3 is predominantly soluble and not packaged in extracellular vesicles.

A

Cytosolic fraction

<table>
<thead>
<tr>
<th>Sample</th>
<th>Galectin-3 (10s)</th>
<th>Actin (30s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>sHeLa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgMGAT1 pos</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgMGAT1 neg cl1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgMGAT1 neg cl2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

100,000g EV pellet

<table>
<thead>
<tr>
<th>Sample</th>
<th>Galectin-3</th>
<th>Actin</th>
<th>CD63</th>
</tr>
</thead>
<tbody>
<tr>
<td>sHeLa</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgMGAT1 pos</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgMGAT1 neg cl1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgMGAT1 neg cl2</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Supernatant

<table>
<thead>
<tr>
<th>Sample</th>
<th>Galectin-3 (5s)</th>
<th>Actin (25s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>sHeLa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgMGAT1 pos</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgMGAT1 neg cl1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgMGAT1 neg cl2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

Cytosolic fraction

<table>
<thead>
<tr>
<th>Sample</th>
<th>Galectin-3 (10s)</th>
<th>Actin (30s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>sHeLa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgSCL35A2 pos</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgSCL35A2 neg cl1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgSCL35A2 neg cl2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

100,000g EV pellet

<table>
<thead>
<tr>
<th>Sample</th>
<th>Galectin-3</th>
<th>Actin</th>
<th>CD63</th>
</tr>
</thead>
<tbody>
<tr>
<td>sHeLa</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgSCL35A2 pos</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgSCL35A2 neg cl1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgSCL35A2 neg cl2</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Supernatant

<table>
<thead>
<tr>
<th>Sample</th>
<th>Galectin-3 (5s)</th>
<th>Actin (25s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>sHeLa</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgSCL35A2 pos</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgSCL35A2 neg cl1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>sgSCL35A2 neg cl2</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

C

Cytosolic fraction

<table>
<thead>
<tr>
<th>Sample</th>
<th>Galectin-3 (5s)</th>
<th>Actin (25s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>wt (Pro5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGAT1 mut (Lec1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGAT1 rescue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLC35A2 mut (Lec8) (Lec3.2.8.1)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

100,000g EV pellet

<table>
<thead>
<tr>
<th>Sample</th>
<th>Galectin-3</th>
<th>Actin</th>
</tr>
</thead>
<tbody>
<tr>
<td>wt (Pro5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGAT1 mut (Lec1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGAT1 rescue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLC35A2 mut (Lec8) (Lec3.2.8.1)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Supernatant

<table>
<thead>
<tr>
<th>Sample</th>
<th>Galectin-3 (5s)</th>
<th>Actin (25s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>wt (Pro5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGAT1 mut (Lec1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MGAT1 rescue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SLC35A2 mut (Lec8) (Lec3.2.8.1)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 6. Recruitment of GFP-Gal3 to damaged lysosomes is reduced in MGAT1 and SLC35A2 deficient cells.

A

- LLOMe

+ LLOMe

control

MGAT1 ko (C1)

SLC35A2 ko (C1)

GFP-Gal3  LAMP2  merged

GFP-Gal3  LAMP2  merged

GFP-Gal3  LAMP2  merged

GFP-Gal3  LAMP2  merged

B

- LLOMe

+ LLOMe

control

MGAT1 ko (C1)

SLC35A2 ko (C1)

GFP-Gal3  mRFP-LC3  merged

GFP-Gal3  mRFP-LC3  merged

GFP-Gal3  mRFP-LC3  merged

GFP-Gal3  mRFP-LC3  merged

Fluorescence intensity (A.U.)

LAMP2  Gal-3  LAMP2  Gal-3

- LLOMe  + LLOMe

Gal-3/LC co-localization

Control  MGAT1 ko (C1)  SLC35A2 ko (C1)
Figure S1. Gal-3 localisation in cytosol, cell surface and supernatant.

A

GeoMean:
No antibody: 1.5
Gal-3 live cells: 22
Gal-3 fix cells: 1754

Counts

10^3 10^4 10^5 10^6 10^7 10^8

Galectin-3

B

Lysates  Supernatants

Gal-3 (20s)
Gal-3 (120s)
Secreted fraction (% supernatant/lysate)
<0.7 <0.2 <0.6 <0.9
Actin (20s)
Actin (300s)
Figure S2. LC3, Vps4 and GRASP55 do not regulate cell surface Gal-3.

A

B

C

**Figure S2.** LC3, Vps4 and GRASP55 do not regulate cell surface Gal-3.

**A.**
- **Parental LC3 ko**
- **Parental GABARAP ko**

**Graph:** Counts of Galectin-3.

**Graph:** Cell surface Galectin-3 (fold change).

**Image:** Western blot for LC3, GABARAP and Actin.

**B.**
- **Control**
- **GRASP55 esiRNA**

**Graph:** Cell surface Galectin-3 (fold change).

**Image:** Western blot for Actin, GRASP55 and Galectin-3.

**C.**

**Graph:** Cell surface Galectin-3 fluorescence intensity (A.U.)
- **No Ab**
- **GFP alone**
- **Vps4 WT**
- **Vps4 EC**

**NS**

**NS**

**NS**
Figure S3. Generation of MGAT1 and SLC35A2 knockout sHeLa cells using CRISPR/Cas9.

A  

Unstained sHeLa  |  sHeLa Gal-3  |  MGAT1 Gal-3  |  SLC35A2 Gal-3  

Galactin-3  

98.7%  |  0.15%  |  5.33%  |  24.3%  

Gal-3 positive clones  |  Gal-3 negative clones  

B  

MOAT1 sgRNA  

MOAT1-WT  

MOAT1-pos  

MOAT1-neg-c1  

MOAT1-neg-c2  

C  

sgMGAT1-pos  

R² = 1  

p < 0.001  

sgMGAT1-neg-c1  

R² = 0.99  

p < 0.001  

sgMGAT1-neg-c2  

R² = 0.97  

p < 0.001  

D  

SLC35A2 sgRNA  

SLC35A2-MT  

SLC35A2-pos  

SLC35A2-neg-c1  

SLC35A2-neg-c2  

E  

sgSLC35A2-pos  

R² = 1  

p < 0.001  

sgSLC35A2-neg-c1  

R² = 0.99  

p < 0.001  

sgSLC35A2-neg-c2  

R² = 0.37  

p < 0.001
Figure S4. Gal-1 is secreted from SLC35A2 deficient sHeLa.
Figure S5. Gal-3 R186S mutant does not have a secretion defect.
Table S1. Enriched genes identified in the genome-wide CRISPR screen for Gal-3 cell surface localisation

See excel file attached
Table S2. Primers used in this study

<table>
<thead>
<tr>
<th>Name</th>
<th>Oligonucleotide sequence 5'-3'</th>
<th>Application</th>
</tr>
</thead>
<tbody>
<tr>
<td>MGAT1 sgRNA</td>
<td>GATGGGAAGAGCTCAGCCG</td>
<td>sgRNA for CRISPR/Cas9 knockout</td>
</tr>
<tr>
<td>MGAT1_F</td>
<td>GGCGAGGAAATCTCGGTGAC</td>
<td>Amplification forward primer</td>
</tr>
<tr>
<td>MGAT1_R</td>
<td>CCTCACCGGGAAGTGATTC</td>
<td>Amplification and sequencing reverse primer</td>
</tr>
<tr>
<td>SLC35A2 sgRNA</td>
<td>GGCAGATGCAACATGGCAG</td>
<td>sgRNA for CRISPR/Cas9 knockout</td>
</tr>
<tr>
<td>SLC35A2_F</td>
<td>TCAGAATGTCTTCTTTCCCGC</td>
<td>Amplification and sequencing forward primer</td>
</tr>
<tr>
<td>SLC35A2_R</td>
<td>TCTCTGACCTCGCACCCTGATG</td>
<td>Amplification reverse primer</td>
</tr>
</tbody>
</table>

**CRISPR screen analysis**

<table>
<thead>
<tr>
<th>sgRNA_outer_F</th>
<th>GCTTACGTAACGTAAGTATTTCC</th>
<th>Forward PCR1 primer</th>
</tr>
</thead>
<tbody>
<tr>
<td>sgRNA_outer_R</td>
<td>GTCTGGCTATTATGTCTATTCTATTCC</td>
<td>Reverse PCR1 primer</td>
</tr>
<tr>
<td>P5-sgRNA_inner_F</td>
<td>AATGATACGGGCGACCAGGGATCTACACTC</td>
<td>Forward PCR2 primer with Illumina P5</td>
</tr>
<tr>
<td></td>
<td>TCTGTGGAAAGGAGAACCCCG</td>
<td></td>
</tr>
<tr>
<td>P7-index-sgRNA_inner_R</td>
<td>CAAGCAGAAGCGCACTACGAGATACAG</td>
<td>Reverse PCR2 primer with Illumina P7 and index</td>
</tr>
<tr>
<td></td>
<td>GTCGACTGGAGTTCAAGCAGTGTGCTTCCGA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TCTCTAATTTCTCTCTCTGACTG</td>
<td></td>
</tr>
<tr>
<td>Illumina sequencing</td>
<td>ACACTCTGGGGAAGGACGAAACCCG</td>
<td>Custom sgRNA sequencing primer</td>
</tr>
<tr>
<td>primer</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>